Why patients with large B-cell lymphoma fail CAR-T therapy & how to manage them

Chimeric antigen receptor (CAR) T cell therapy has been in the spotlight due to its ability to achieve lasting remissions in 40-50% of patients with large B-cell lymphoma (DLBCL), who relapse after ³2 lines of conventional therapy.1 To date, most of the